# An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

> **NCT00444340** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 70 (—)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Enbrel (Etanercept)

## Key facts

- **NCT ID:** NCT00444340
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 70 (—)
- **Last updated:** 2007-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00444340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00444340, "An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00444340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*